TIANDA PHARMA(00455.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of HKD 32.25 million, loss narrowed by 2.97% YoY
NewTimeSpace News: August 10, 2026, TIANDA PHARMA(00455.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 164.22 million, increased by 20.19% YoY; Net Profit stood at loss of HKD 32.22 million, loss narrowed by 3.82% YoY; Profit Attributable to Shareholders stood at loss of HKD 32.25 million, loss narrowed by 2.97% YoY; Basic Earnings Per Share (EPS) stood at loss of HK cents 1.5.
In terms of profitability, TIANDA PHARMA Gross Profit changed from HKD 56.58 million in the same period last year to HKD 66.14 million in the current period, increased by HKD 9.56 million; gross profit margin changed from 41.41% in the same period last year to 40.28% in the current period, decreased by 1.14 percentage points; net profit changed from loss of HKD 33.5 million in the same period last year to loss of HKD 32.22 million in the current period, increased by HKD 1.28 million; net profit margin changed from -24.52% in the same period last year to -19.62% in the current period, increased by 4.9 percentage points.
In terms of earnings quality, TIANDA PHARMA Operating Profit changed from loss of HKD 32.1 million in the same period last year to loss of HKD 29.12 million in the current period, increased by HKD 2.98 million; Operating Profit Margin changed from -23.49% in the same period last year to -17.73% in the current period, increased by 5.76 percentage points.
In terms of financial soundness, TIANDA PHARMA Debt-to-Asset Ratio changed from 37.34% in the same period last year to 41.03% in the current period, increased by 3.69 percentage points; Total Equity changed from HKD 485.5 million in the same period last year to HKD 441.187 million in the current period, decreased by HKD 44.31 million; Current Liabilities changed from HKD 233.49 million in the same period last year to HKD 282.18 million in the current period, increased by HKD 48.69 million; Quick Ratio changed from 0.69 in the same period last year to 0.48 in the current period, decreased by 0.21 percentage points.
In terms of R&D investment focus, TIANDA PHARMA R&D Expenses changed from HKD 5.95 million in the same period last year to HKD 2.71 million in the current period, decreased by HKD 3.24 million; R&D to Total Revenue Ratio changed from 4.36% in the same period last year to 1.65% in the current period, decreased by 2.71 percentage points.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
